Search clinical trials for: Romiplostim

Total 74 results

Weill Medical College of Cornell University
GlaxoSmithKline

Completed

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenia

United States
Assistance Publique - Hôpitaux de Paris

Completed

Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell (AGRAH003)

Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

France
Amgen

Completed

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Myelodysplastic Syndromes | Thrombocytopenia | MDS
NYU Langone Health
National Cancer Institute (NCI)

Terminated

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Thrombocytopenia | Refractory Multiple Myeloma

United States
Nantes University Hospital

Completed

Romiplostim in Thoracic Transplantation (N-PLATE)

Thrombocytopenia
University Hospital, Lille

Terminated

Prevention of Thrombocytopenia in Glioblastoma Patients (PLATUM)

Glioblastoma | Thrombocytopenia

France
Amgen

Withdrawn

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.

Chemotherapy-induced Thrombocytopenia
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
GlaxoSmithKline

Completed

Indirect Comparison Between Eltrombopag & Romiplostim

Thrombocytopaenia
University of Southern California

Terminated

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Thrombocytopenia | Hepatitis C Infection

United States
Boston University
Family Planning Fellowship

Completed

Same-day Long-acting Reversible Contraception for Medication Abortion (SaLMA)

Abortion; Induced

United States
Amgen

Completed

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura

United States, Canada, Australia
Weill Medical College of Cornell University
Children's Hospital of Orange County

Completed

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

Immune Thrombocytopenia

United States
Amgen

Completed

Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training

Immune Thrombocytopenic Purpura

Spain, Austria, Belgium, Greece, United Kingdom, France, Germany, Netherlands
Samsung Medical Center

Unknown

An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP

Immune Thrombocytopenia
Kyowa Kirin Co., Ltd.

Completed

Safety Study of AMG 531 in Japanese Subjects With ITP

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
M.D. Anderson Cancer Center
Amgen

Completed

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Advanced Cancer | Solid Tumors

United States
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
Amgen

Completed

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Cancer | Lung Neoplasms | Non-Small Cell Lung Cancer | Thrombocytopenia | Lung Cancer | Solid Tumors | Oncology | Chemotherapy-Induced Thrombocytopenia

United States, Canada, Italy, Germany, Austria, Hungary, Portugal, Ireland
GlaxoSmithKline

Completed

Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

Immune Thrombocytopenic Purpura
Henri Mondor University Hospital
Paris 12 Val de Marne University

Completed

Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

Immune Thrombocytopenia | Thrombopoietin Receptor Agonist
Henri Mondor University Hospital
Amgen; Paris 12 Val de Marne University

Completed

Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults (ATU-r)

Thrombopenia

Search clinical trials for: Romiplostim

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations